Research and analysis

ACMD advice on consumer cannabidiol (CBD) products

Report from the Advisory Council on the Misuse of Drugs (ACMD) on consumer cannabidiol (CBD) products.

From:
Advisory Council on the Misuse of Drugs
Published
17 December 2021
Last updated
24 October 2023 — See all updates

Documents

Consumer CBD products report (accessible version)

HTML

Consumer CBD products report

PDF, 714 KB, 42 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Cover letter from ACMD on consumer CBD products report (accessible version)

HTML

Cover letter from ACMD on consumer CBD products report

PDF, 202 KB, 4 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Letter from the ACMD advising on the exempt product definition in the Misuse of Drugs Regulations 2001 (accessible version)

HTML

Letter from the ACMD advising on the exempt product definition in the Misuse of Drugs Regulations 2001

PDF, 214 KB, 4 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Government response to the ACMD’s advice on consumer CBD products (accessible version)

HTML

Government response to the ACMD’s advice on consumer CBD products

PDF, 158 KB, 3 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The ministerial commission asked the ACMD to specify which controlled cannabinoids should be controlled and set an unavoidable trace level for each of these within consumer CBD products.

Updates to this page

Published 17 December 2021
Last updated 24 October 2023 + show all updates

  1. The government’s response to the ACMD’s advice has been added.

  2. Added HTML accessible version of documents.

  3. First published.

Sign up for emails or print this page